Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase I-studie av XH-S003 i friske frivillige

En fase I-studie for å vurdere sikkerheten, tolerabiliteten og farmakokinetikken til XH-S003 etter enkeltstående stigende doser, flere stigende doser og evaluering av mateffekter hos friske frivillige

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

36

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Beijing, Kina
        • Beijing Friendship Hospital,Capital Medical University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female, aged ≥ 18 to ≤ 55 years old.

  2. BMI between ≥ 19.0 and ≤ 30.0 kg/m2 at Screening, and weight between ≥ 50 kg and ≤ 120.0kg for male, weight ≥ 45 kg and ≤ 120.0kg for female.

  3. Able and willing to comply with the study procedure and the restriction specified in the protocol.

  4. Provision of signed and dated written informed consent prior to any study specific procedures.

  5. Female subjects of childbearing potential must have a negative serum pregnancy test result at screening and a negative pregnancy test result at baseline, and agree to use one of the acceptable methods of contraception listed below during the study (from the time of signing the informed consent until one month after the end of study [EOS] or early termination visit evaluation [ET]):

    • The subject's male partner has undergone documented vasectomy with documentation of azoospermia (male sterilization).
    • A documented placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • Consistent use of the same oral contraceptives for at least 3 months before screening, injectable progesterone, subdermal implants, or the use of a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps], which present no effect on IP at the discretion of investigator).
    • Documented tubal ligation (female sterilization).
    • True abstinence: when this is in line with the preferred and usual lifestyle of the subject, including female subjects with same sex partners. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Abstinent subjects must agree to use one of the above-mentioned contraceptive methods, if they start sexual relationships during the study.

Exclusion Criteria:

  1. Subjects with a history of allergies to similar ingredients of the study drug or any ingredient in the study drug, or vaccine component; subjects with a history of severe allergic or anaphylactic reactions at the discretion of PI. Subjects with one of the conditions (including, but not limited to):

    • Subjects with history of eczema within 3 years.
    • Subjects with asthma except for resolved childhood asthma.
    • Subjects with clinical syndromes of urticaria at screening or baseline.
  2. Subjects whose abnormalities in past medical history are clinically significant or other clinical findings suggest the following clinically significant diseases at the discretion of the PI (including but not limited to gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, pulmonary, psychiatric, or cardiovascular and cerebrovascular diseases, which are deemed as clinically significant by PI).

  3. Abnormal liver function tests at screening, defined as alanine aminotransferase (ALT) or aspartate transaminase (AST) > 1.5x upper limit of normal (ULN), and bilirubin >1.5x ULN (isolated bilirubin > 1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) that are considered by the PI to be clinically significant. Repeat tests are permitted at investigator discretion.

  4. Abnormal ECG findings at Screening or Day -1 (eg, repeated demonstration of a QTc interval > 450 ms [male] or > 470 ms [female] corrected by Fridericia's formula [QTcF] or Bazett's formula [QTcB]; heart rate [HR] is out of normal range 45-100 bmp; PR is out of normal range 120 -220 msec; QRS is out of normal range <120msec) that are considered by the PI or designee to be clinically significant. Repeat tests are permitted at investigator discretion.

  5. Subjects with clinically significant infection (e.g., requiring hospitalization or parenteral antimicrobial therapy) within 2 months before screening or active systemic bacterial, viral, or fungal infection or fever with ear temperature > 37.7℃ within 2 weeks before screening at the discretion of the PI.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Experimental: A (XH-S003)

Participants will receive XH-S003 once or twice daily on scheduled day(s)

IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Placebo komparator: Placebo Comparator: B (Placebo)

Participants will receive matching placebo once daily on scheduled day(s)

Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with adverse events (AEs)
Tidsramme: Part A: Approximately 1~2 weeks

Safety and tolerability evaluation: All participants were observed for any adverse events that occurred during the clinical study, including abnormalities in clinical symptoms and vital signs, physical examination, laboratory examination, and 12-lead electrocardiogram, and were determined to be associated with the investigational drug.

Part A: Approximately 1~2 weeks
Number of participants with adverse events (AEs)
Tidsramme: Part B: Approximately 3~4weeks

Safety and tolerability evaluation: All participants were observed for any adverse events that occurred during the clinical study, including abnormalities in clinical symptoms and vital signs, physical examination, laboratory examination, and 12-lead electrocardiogram, and were determined to be associated with the investigational drug.

Part B: Approximately 3~4weeks
Number of participants with adverse events (AEs)
Tidsramme: Part C: Approximately 3~4weeks

Safety and tolerability evaluation: All participants were observed for any adverse events that occurred during the clinical study, including abnormalities in clinical symptoms and vital signs, physical examination, laboratory examination, and 12-lead electrocardiogram, and were determined to be associated with the investigational drug.

Part C: Approximately 3~4weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. juli 2023

Primær fullføring (Faktiske)

30. juli 2024

Studiet fullført (Faktiske)

30. november 2024

Datoer for studieregistrering

Først innsendt

15. februar 2024

Først innsendt som oppfylte QC-kriteriene

15. februar 2024

Først lagt ut (Faktiske)

22. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. mai 2025

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • XH-S003-I-101

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere